Joyce Meghan V. sold $1.3M of GH

Joyce Meghan V. sold 10,000 shares of Guardant Health, Inc. (GH) at an average of $126.98 ($126.52–$129.31, $1.27M total) across 4 trades on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Joyce Meghan V.
Published Jun 4, 2026, 10:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Bearish
high confidence
Mentioned
$GH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHBearishLow
01

Why it matters

The disclosed sale may prompt short‑term traders to watch GH for potential price dip, though the pre‑arranged nature tempers significance.

02

Market read

Routine insider sale with modest size; limited impact on broader market.

03

What to watch

The 10b5-1 plan indicates the sale was pre‑scheduled, reducing the informational content of the transaction.

Relevance 5/10Novelty 4/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$GHBearishHigh confidence
Context

Director Joyce Meghan V. sold 10,000 shares for $1.27M via a 10b5-1 plan, reducing her stake to 11,183 shares.

Expected impact

likely slight downward pressure as investors price in the insider sell.

Evidence & confidence

Director-level insider sold a sizable block at market price; such sales often prompt short-term sell‑offs.

Market effects

Minimal; Guardant operates in liquid biopsy sector, but a single insider sale does not shift sector outlook.

None; the filing is company‑specific.

Low; no broader market effect.

Counterpoint

The sale could be purely portfolio rebalancing under a pre‑arranged plan, not a negative signal.

Key entities

  • Guardant Health, Inc.

    NASDAQ‑listed liquid biopsy company.

  • Joyce Meghan V.

    Director of Guardant Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.